- Home
- URG vs ARVN Comparison
URG vs ARVN Comparison
Compare URG & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URG | ARVN |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 699.8M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | URG | ARVN |
|---|---|---|
| Price | $1.87 | $12.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 23 |
| Target Price | $2.52 | ★ $18.14 |
| AVG Volume (30 Days) | ★ 9.9M | 677.4K |
| Earning Date | 11-03-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $39,411,000.00 | ★ $312,300,000.00 |
| Revenue This Year | N/A | $10.55 |
| Revenue Next Year | $183.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 138.94 | 93.86 |
| 52 Week Low | $0.55 | $5.90 |
| 52 Week High | $2.35 | $20.38 |
Technical Indicators
Market Signals| Indicator | URG | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 71.80 | 61.60 |
| Support Level | $1.81 | $11.82 |
| Resistance Level | $2.00 | $13.19 |
| Average True Range (ATR) | 0.09 | 0.61 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 71.28 | 86.73 |
Price Performance
Historical ComparisonAbout URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.